Mecamylamine for Autonomic Dysreflexia Prophylaxis

• Status: Unknown status
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a preliminary study of the antihypertensive drug mecamylamine, used in the specific circumstance of hypertension caused by autonomic dysreflexia (AD), a condition that affects people with spinal cord injury (SCI). Initially, mild sensory stimulation of subjects' legs is used to intentionally provoke AD, as reflected by blood pressure elevation during such stimulation. In subsequent testing sessions, mecamylamine is given prior to sensory stimulation, to show the effect of the drug on preventing these AD-related blood pressure elevations.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wayne State University
• Treatments: Mecamylamine

Criteria

Inclusion Criteria:

• chronic (>1 year) SCI at T6 or above, American Spinal Injury Association grade A, B, or C

• negative serum pregnancy test for females

Exclusion Criteria:

• history of arrhythmia, cardiovascular disease, cerebral aneurysm

• contraindications to use of mecamylamine or midodrine (pregnancy, nursing, glaucoma, kidney disease, pyloric stenosis, arteriosclerosis, or concurrent use of a sulfonamide antibiotic)

• dependence on reflex voiding for bladder management (mecamylamine may cause urinary retention)